Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988319 · ClinicalTrials.gov registry record · Phase 1
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
A Phase 1 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06988319 is a Phase 1 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 15 participants.
The verdict
NCT06988319, a Phase 1 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).
Interventions
- DRUG Psilocybin (Usona Institute)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06988319
The ClinicalTrials.gov registry entry for NCT06988319 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin (Usona Institute) is the first listed.
NCT06988319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06988319 about?
NCT06988319 is a clinical study titled "Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study". The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychother...
What is the current status of trial NCT06988319?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-01-01. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT06988319?
The interventions under investigation include: Psilocybin (Usona Institute) (DRUG).
Who is sponsoring clinical trial NCT06988319?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.